APA (7th ed.) Citation

Capdevila Castillon, J., Plana, M., Castelo, B., Iglesias, L., Hernando, J., Yaya Tur, R., . . . Alonso-Gordoa, T. (2022). 1645O Durvalumab (D) plus tremelimumab (T) for the treatment of patients with progressive, refractory advanced thyroid carcinoma: The DUTHY (GETNE-T1812) trial. Annals of Oncology, 33, S1294. https://doi.org/10.1016/j.annonc.2022.07.1725

Chicago Style (17th ed.) Citation

Capdevila Castillon, J., et al. "1645O Durvalumab (D) Plus Tremelimumab (T) for the Treatment of Patients with Progressive, Refractory Advanced Thyroid Carcinoma: The DUTHY (GETNE-T1812) Trial." Annals of Oncology 33 (2022): S1294. https://doi.org/10.1016/j.annonc.2022.07.1725.

MLA (9th ed.) Citation

Capdevila Castillon, J., et al. "1645O Durvalumab (D) Plus Tremelimumab (T) for the Treatment of Patients with Progressive, Refractory Advanced Thyroid Carcinoma: The DUTHY (GETNE-T1812) Trial." Annals of Oncology, vol. 33, 2022, p. S1294, https://doi.org/10.1016/j.annonc.2022.07.1725.